AbCellera Biologics Inc. (ABCL) 주식 분석

회사 개요

AbCellera Biologics Inc. is a healthcare enterprise focused on the discovery and development of antibody-based medicines designed to address unmet medical needs within the United States market. The company operates specifically within the biotechnology industry, a sector characterized by high research and development costs and long product development cycles that aim to deliver novel therapeutic solutions. As of the latest reporting period, the company maintains a market capitalization of $1.04 billion and employs 562 individuals across its operational footprint. The company recorded annual revenue of $75.13 million, figures which indicate that the firm is currently in a growth phase typical for biotechnology entities where revenue is being scaled through clinical progress rather than established commercial sales.

재무 건전성

The company reported total revenue of $75.13 million over the trailing twelve months, yet simultaneously posted a net income loss of $146.41 million and an EBITDA loss of $194.93 million. This significant divergence between positive revenue and substantial net income losses reveals a cost structure dominated by high operating expenses, likely driven by clinical trial costs and R&D expenditures common in the biotechnology sector. Free cash flow stood at a negative $175.997376 million, indicating that the company is currently burning cash, which implies limited financial flexibility and a reliance on external capital sources or existing cash reserves to fund operations. The gross margin is reported at -148.7%, the operating margin at -63.7%, and the profit margin at -194.9%; these negative figures reflect that operating expenses significantly exceed gross revenue, a standard characteristic for pre-commercial biotechnology companies before product launch. On the balance sheet, the company holds $533.83 million in cash against $143.22 million in debt, resulting in a debt-to-equity ratio of 14.81, which suggests a leveraged position despite the high level of available liquidity. The current ratio is 11.32, a metric that indicates strong short-term liquidity and the ability to cover current liabilities more than eleven times with current assets. Return on equity stands at -14.5% and return on assets at -10.0%, metrics that reveal that management has not yet generated positive returns on the capital base due to the ongoing investment phase of the business.

밸류에이션 평가

Trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E ratio is listed at -4.47, a valuation metric that implies the market is pricing in future earnings expectations that are currently undefined or negative. The price-to-book ratio is 1.07, suggesting that the market values the company at a slight premium relative to its book value, which can occur when investors anticipate significant intangible assets or future commercial potential not yet reflected on the balance sheet. Alternative valuation metrics show a price-to-sales ratio of 13.88 and an EV/EBITDA of -3.35, figures that suggest the market is valuing the company primarily on revenue generation and growth prospects rather than current profitability or cash earnings. The stock has traded between a 52-week high of $6.51 and a 52-week low of $1.90, providing a trading range within which the current price fluctuates based on market sentiment regarding clinical milestones. The beta value of 0.85 indicates that the stock price exhibits volatility that is slightly lower than the broader market, suggesting a moderate correlation with overall market movements.

Growth & Income

Revenue growth year-over-year reached an impressive 788.2%, whereas earnings growth is not applicable due to the company's current loss-making status, implying that top-line expansion is occurring faster than profitability can be realized in this early-stage development context. The company does not pay dividends, evidenced by a dividend yield of not available and a payout ratio of 0.0%, meaning that all available earnings and cash flow are being retained within the business to fund research and development activities rather than being distributed to shareholders. This reinvestment strategy is standard for biotechnology firms in the discovery and clinical trial phases, where capital preservation and growth funding are prioritized over income generation for investors. Overall, the growth and income profile of AbCellera Biologics Inc. is characterized by aggressive revenue expansion and zero current income distribution, reflecting a business model focused on long-term asset creation through clinical trial advancement.